Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG | Grabenstrasse 11a, 8952 Schlieren, Switzerland
Zurich-Schlieren, Switzerland, July 1st, 2021. TOPADUR Pharma AG, a biopharmaceutical start-up company today is pleased to announce the submission of an application to the European Medicines Agency (EMA) to receive Orphan Drug Designation (ODD) status for its lead product TOP-N53 to treat digital ulcers in patients with systemic sclerosis.
“The submission of our ODD represents a major milestone for the Company and it brings significant benefits to the development process of TOP-N53,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “We believe that TOP-N53 has significant potential to provide a valuable treatment option for digital ulcers in patients afflicted by systemic sclerosis, a disabling condition.”
Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.
Read moreTOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.
Read moreThe European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.
Read more
